Last 12 months
Inside the activity.
0 purchase rows · 93 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 6 |
| Dec 2025 | 0 | 16 |
| Jan 2026 | 0 | 2 |
| Feb 2026 | 0 | 49 |
| Mar 2026 | 0 | 5 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 6 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 3 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 12, 2023 Filed Apr 14, 2023 20:14 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 10,357 | $326.46 | $3,381,146.22 |
DisclosureSEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 3 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,236 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022. F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $326.46 (range $326.00 to $326.97). Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:14 UTC |
SACHS BRUCE IDirector
|
SaleCommon Stock | 2,917 | $325.65 | $949,921.05 |
DisclosureSEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 2 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 59,593 F1 · kind: Transaction made pursuant to Mr. Sachs' company approved trading plan under Rule 10b5-1, which was entered into on 11/04/2022. F2 · price: Mr. Sachs undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $325.65 (range $325.00 to $325.99). Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:14 UTC |
SACHS BRUCE IDirector
|
Exercise / conversionCommon Stock | 21,300 | $72.14 | $1,536,582.00 |
DisclosureSEC source: 0001209191-23-024305 · doc4.xml · nonDerivative · entry 1 SACHS BRUCE I · CIK 0001197036 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 62,510 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:19 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 2,625 | $327.43 | $859,503.75 |
DisclosureSEC source: 0001209191-23-024312 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,713 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $327.43 (range $327.01 to $327.91). Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:19 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 4,068 | $326.45 | $1,327,998.60 |
DisclosureSEC source: 0001209191-23-024312 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 42,338 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $326.45 (range $326.00 to $326.99). Read SEC document |
| April 12, 2023 Filed Apr 14, 2023 20:19 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 874 | $325.70 | $284,661.80 |
DisclosureSEC source: 0001209191-23-024312 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,406 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $325.70 (range $325.00 to $325.98). Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 31 | $318.68 | $9,879.08 |
DisclosureSEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 5 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,280 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 96 | $317.65 | $30,494.40 |
DisclosureSEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 4 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,311 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $317.65 (range $317.49 to $317.74). Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 90 | $316.76 | $28,508.40 |
DisclosureSEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 3 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,407 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $316.76 (range $316.41 to $317.20). Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 94 | $315.66 | $29,672.04 |
DisclosureSEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,497 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $315.66 (range $315.08 to $315.96). Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 20:23 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 211 | $314.22 | $66,300.42 |
DisclosureSEC source: 0001209191-23-023588 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,591 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was entered into on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $314.22 (range $313.72 to $314.70). Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:18 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 176 | $313.74 | $55,218.24 |
DisclosureSEC source: 0001209191-23-022689 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,127 Read SEC document |
| March 31, 2023 Filed Apr 4, 2023 20:20 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
Tax withholdingCommon Stock | 1,466 | $313.74 | $459,942.84 |
DisclosureSEC source: 0001209191-23-022695 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,802 Read SEC document |
| March 24, 2023 Filed Mar 28, 2023 20:13 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 1,768 | $305.38 | $539,911.84 |
DisclosureSEC source: 0001209191-23-021394 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,611 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was entered into on 08/08/2022. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 16 | $301.13 | $4,818.08 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 6 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,379 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 240 | $299.58 | $71,899.20 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,395 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $299.58 (range $299.09 to $300.06). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 360 | $298.09 | $107,312.40 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,635 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $298.09 (range $297.65 to $298.48). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 240 | $296.30 | $71,112.00 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,995 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $296.30 (range $296.14 to $296.45). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 784 | $295.43 | $231,617.12 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,235 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $295.43 (range $295.09 to $295.97). Read SEC document |
| March 17, 2023 Filed Mar 21, 2023 20:21 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 360 | $294.52 | $106,027.20 |
DisclosureSEC source: 0001209191-23-020244 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,019 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1, which was adopted on 08/08/2022. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $294.52 (range $293.98 to $294.81). Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 264 | $301.07 | $79,482.48 |
DisclosureSEC source: 0001209191-23-020043 · doc4.xml · nonDerivative · entry 2 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,268 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was adopted on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $301.07 (range $301.00 to $301.14). Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 20:26 UTC |
Sanna BastianoEVP, Cell & Genetic Therapies
|
SaleCommon Stock | 2,482 | $300.54 | $745,940.28 |
DisclosureSEC source: 0001209191-23-020043 · doc4.xml · nonDerivative · entry 1 Sanna Bastiano · CIK 0001829069 · EVP, Cell & Genetic Therapies 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,532 F1 · kind: Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1, which was adopted on 08/10/2022. F2 · price: Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $300.54 (range $300.00 to $300.94). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 62 | $296.77 | $18,399.74 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 14 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,379 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 292 | $295.89 | $86,399.88 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 13 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,441 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F12 · price: Open market sales reported on this line occurred at a weighted average price of $295.89 (range $295.33 to $296.32). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 715 | $294.52 | $210,581.80 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 12 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,733 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F11 · price: Open market sales reported on this line occurred at a weighted average price of $294.52 (range $294.13 to $294.81). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 1,153 | $293.35 | $338,232.55 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 11 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,448 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F10 · price: Open market sales reported on this line occurred at a weighted average price of $293.35 (range $292.99 to $293.80). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 420 | $292.41 | $122,812.20 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 10 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,061 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $292.41 (range $291.97 to $292.82). Read SEC document |
| March 13, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 24 | $288.31 | $6,919.44 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 9 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,021 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 102 | $294.94 | $30,083.88 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 8 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,045 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $294.94 (range $294.85 to $295.35). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 27 | $293.61 | $7,927.47 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 7 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,147 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 185 | $292.68 | $54,145.80 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 6 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,174 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $292.68 (range $292.14 to $293.12). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 541 | $291.47 | $157,685.27 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 5 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,359 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $291.47 (range $291.10 to $292.00). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 30 | $289.44 | $8,683.20 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 4 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,900 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 327 | $288.91 | $94,473.57 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 3 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,930 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $288.91 (range $288.37 to $289.34). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 515 | $287.83 | $148,232.45 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 2 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,257 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $287.83 (range $287.30 to $288.20). Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:22 UTC |
WAGNER CHARLES F JREVP & Chief Financial Officer
|
SaleCommon Stock | 361 | $286.64 | $103,477.04 |
DisclosureSEC source: 0001209191-23-018460 · doc4.xml · nonDerivative · entry 1 WAGNER CHARLES F JR · CIK 0001223348 · EVP & Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,772 F1 · kind: Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $286.64 (range $286.17 to $287.16). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 302 | $289.60 | $87,459.20 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 4 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,038 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $289.60 (range $289.49 to $289.65). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 300 | $288.74 | $86,622.00 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 3 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,340 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.74 (range $288.42 to $289.37). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
SaleCommon Stock | 3,636 | $287.23 | $1,044,368.28 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 2 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,640 F1 · kind: Transaction made pursuant to Dr. Altshuler's company approved trading plan under Rule 10b5-1. F2 · price: Dr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.23 (range $286.80 to $287.72). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:44 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 42 | $289.63 | $12,164.46 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 4 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,303 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:44 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 183 | $288.68 | $52,828.44 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 3 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,345 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.68 (range $288.24 to $289.17). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:44 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
SaleCommon Stock | 982 | $287.25 | $282,079.50 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 2 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,528 F1 · kind: Transaction made pursuant to Ms. Ambrose's company approved trading plan under Rule 10b5-1. F2 · price: Ms. Ambrose undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.25 (range $286.79 to $287.71). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:47 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 800 | $288.92 | $231,136.00 |
DisclosureSEC source: 0001209191-23-013708 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,556 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $288.92 (range $288.57 to $289.38). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:47 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 400 | $287.59 | $115,036.00 |
DisclosureSEC source: 0001209191-23-013708 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,356 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $287.59 (range $287.57 to $287.60). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 21:47 UTC |
Arbuckle Stuart AEVP, COO
|
SaleCommon Stock | 3,834 | $287.16 | $1,100,971.44 |
DisclosureSEC source: 0001209191-23-013708 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,756 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.16 (range $286.57 to $287.51). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:11 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 20 | $289.29 | $5,785.80 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 4 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,805 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $289.29 (range $289.17 to $289.40). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:11 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 51 | $288.33 | $14,704.83 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 3 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,825 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $288.33 (range $287.82 to $288.74). Read SEC document |
| February 27, 2023 Filed Feb 28, 2023 22:11 UTC |
Tatsis OuraniaEVP, Chief Reg. & Quality Off.
|
SaleCommon Stock | 283 | $287.20 | $81,277.60 |
DisclosureSEC source: 0001209191-23-013765 · doc4.xml · nonDerivative · entry 2 Tatsis Ourania · CIK 0001789815 · EVP, Chief Reg. & Quality Off. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,876 F1 · kind: Transaction made pursuant to Ms. Tatsis' company approved trading plan under Rule 10b5-1. F2 · price: Ms. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $287.20 (range $286.71 to $287.60). Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:40 UTC |
ALTSHULER DAVIDEVP, Global Research and CSO
|
Tax withholdingCommon Stock | 3,970 | $289.12 | $1,147,806.40 |
DisclosureSEC source: 0001209191-23-013685 · doc4.xml · nonDerivative · entry 1 ALTSHULER DAVID · CIK 0001550395 · EVP, Global Research and CSO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,276 Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:44 UTC |
Ambrose KristenSVP & Chief Accounting Officer
|
Tax withholdingCommon Stock | 502 | $289.12 | $145,138.24 |
DisclosureSEC source: 0001209191-23-013695 · doc4.xml · nonDerivative · entry 1 Ambrose Kristen · CIK 0001856587 · SVP & Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,510 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.